Advances of using antibody against B cell activating factor for treatment of autoimmune diseases / 生物工程学报
Chinese Journal of Biotechnology
; (12): 903-914, 2022.
Article
in Zh
| WPRIM
| ID: wpr-927753
Responsible library:
WPRO
ABSTRACT
In recent decades, the treatment of autoimmune diseases has moved from the use of hormones and conventional immunosuppressive drugs to biological agents. B cell proliferation and maturation play crucial roles in the development of autoimmune diseases. The tumor necrosis factor superfamily ligand B cell activating factor (BAFF) and its receptor mediate B cell survival through regulating signaling pathways. Therefore, BAFF and its receptors are important therapeutic targets for the treatment of autoimmune diseases. This review describes the mechanism of BAFF and its receptor in the human body system and introduces the latest views on how over-activation of BAFF pathway promotes the development of autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, and rheumatoid arthritis. In connection to the treatment of the above three diseases, this review discusses the clinical trials and application status of three BAFF-targeting antibody drugs, including Belimumab, Tabalumab and Atacicept. Finally, this review proposes new strategies that targeting the BAFF pathway to provide a new treatment for autoimmune diseases.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Autoimmune Diseases
/
B-Lymphocytes
/
Interleukin-4
/
B-Cell Activating Factor
/
Lupus Erythematosus, Systemic
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Biotechnology
Year:
2022
Type:
Article